Kidney Week

Abstract: TH-PO931

The Effect of SARS-CoV-2 Vaccination in a Hemodialysis Population in the Region of Southern Denmark

Session Information

• COVID-19: Vaccines and Outcomes ESRD/KTR
  November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
  Abstract Time: 10:00 AM - 12:00 PM

Category: Coronavirus (COVID-19)

• 000 Coronavirus (COVID-19)

Authors

• Thuesen, Anne Daugaard, Sygehus Lillebalt Kolding Sygehus, Kolding, Denmark

Anne Daugaard Thuesen,

• Pedersen, Erik Bo, Odense Universitetshospital, Odense, Syddanmark, Denmark

Erik Bo Pedersen,

• Knudsen, Annie Rosenfeldt, Sygehus Lillebalt Kolding Sygehus, Kolding, Denmark

Annie Rosenfeldt Knudsen,

• Juul-Sandberg, Rikke, Sygehus Lillebalt Kolding Sygehus, Kolding, Denmark

Rikke Juul-Sandberg,

• Knudsen, Majbrittt, Sydvestjysk Sygehus, Esbjerg, Syddanmark, Denmark

Majbrittt Knudsen,

• Nilsson, Christine, Odense Universitetshospital, Odense, Syddanmark, Denmark

Christine Nilsson,

• Jensen, Per B., Odense Universitetshospital, Odense, Syddanmark, Denmark

Per B. Jensen,

• Bistrup, Claus, Odense Universitetshospital, Odense, Syddanmark, Denmark

Claus Bistrup,

Background

Hemodialysis patients are a high-risk, immunocompromised population. Therefore, it is expected that vaccination against SARS Cov-2 will have a reduced efficacy in these patients, who have a high mortality from SARS-CoV-2 infection.

Methods

Prospective observational study performed on three dialysis facilities in the Region of Southern Denmark (Kolding Hospital, Odense University Hospital and Sydvestjysk Hospital Esbjerg) in the period March 2021 through March 2023. SARS CoV-2 anti-S RBD IgG are measured in blood samples collected one, two, five, seventeen and twenty-three month after the second vaccination and furthermore before and one month after the third vaccination see. Anti-S RBD IgG was determined using the SARS-CoV-2 IgG II Quant assay (Abbott Laboratories). Non-responders are defined with anti-S-RBD IgG < 7.1 BAU/ml. All hemodialysis patients received the mRNA vaccine Comirnaty/Pfizer-BioNTech. We have included 249 hemodialysis patients.

Results

Below one percent of the hemodialysis population were infected with the Wild type and Delta COVID-19 variant. Significantly reduction in the anti-S-RBD level from 4 weeks after the second vaccination (mean = 544 BAU/ml SEM ±82) to 20 weeks after (mean = 102.3 BAU/ml SEM±49.1).There was a significant increase in the anti-S RBD level after the third booster vaccination with a large variation (mean = 2403 BAU/ml SEM ±148.3) compared to four weeks after the second (mean = 544 BAU/ml SEM ±82). The fraction of non-responders were markedly reduced after the third vaccination from 26% to 3%. We will present the latest data on the anti-S-RBD level that we continuously measures until March 2023.

Conclusion

Hemodialysis patients seem to loose humoral immunity rapidly after the initial COVID-vaccinations, but gain a significant rise in anti-S RBD antibody levels after the third vaccination. The fraction of non-responders after 3^rd dose decreased to 3%.